Safety of and Immunogenicity to an H1N1 Influenza Vaccine in HIV-infected Adults

NCT01155037 | Completed Phase 2

• 1 other identifier: VIP-H1N1
• Study Type: interventional
• Target: 450
• Locations: 1 country
• Sites: 1

Brief Summary

This is a randomized, open label, phase II trial to evaluate the safety and immunogenicity of two different schedules of vaccination against influenza A H1N1 in HIV-infected individuals, in which each of the randomized groups will be compared with HIV-negative volunteers vaccinated with the regimen indicated by the Brazilian National Immunization Program. Will be included in the study HIV-infected patients, stratified by CD4 count (\< 200 cells/mm3 or \> 200 cells/mm3) at the time of screening for the study, not receiving antiretroviral therapy treatment or receiving stable treatment for at least 8 weeks, with no plans to change over the next 6 months, eligible to receive vaccine against influenza A H1N1. The control group will be formed by HIV-negative individuals, confirmed by serology performed at screening, eligible to receive vaccine against influenza A H1N1. Patients infected with HIV will receive one of two possible vaccination regimens: 1) 3.75 µg in two applications 21 days apart, 2) 7.5 µg in two applications 21 days apart. The volunteers in the control group will receive a single application of 3.75 µg dose of the vaccine. The study's hypotheses are: 1) The vaccine against the H1N1 virus promotes antibody titers above the level specified for protection (seroconversion), being as safe and well tolerated in patients HIV-1 infected as in non HIV-infected volunteers; 2) The proportion of seroconversion for H1N1 virus vaccine at a dose of 3.75 µg in HIV-1-infected patients is similar to the proportion of seroconversion induced by the same vaccine at a dose of 7.5 µg; 3)The proportion of seroconversion with one dose of the vaccine against H1N1 virus is similar to the proportion after the second dose.

Conditions

HIV Infection

Keywords

HIV, influenza A H1N1, vaccine

Outcome Measures

Primary Outcomes (3)

• proportions of seroconversion

  proportions of seroconversion for influenza A H1N1 in each of the four subsets of HIV-positive patients, and in the control group

  21 days after vaccination regimen

• proportions of seroprotection

  proportions of seroprotection for influenza A H1N1 in each of the four subsets of HIV-positive patients and in the control group

  21 days after vaccination regimen

• Safety of the A H1N1 vaccine at two different regimens in HIV-infected adults

  Safety and tolerability of the vaccine against H1N1 virus in different doses and administration regimens in IV-infected adults

  1 months after vaccination

Secondary Outcomes (4)

• Prevalence of A H1N1 influenza symptomatic disease in the study population

  12 months after vaccination

• Persistence of antibodies against H1N1 virus

  12 months after vaccination

• Changes in HIV viral load and CD4

  12 months after vaccination

• Cellular immune responses to H1N1 vaccination in HIV-infected patients

  12 months after vaccination

Study Arms (3)

3.75 µg of the vaccine on days 0 and 21

EXPERIMENTAL

Patients infected with HIV will receive 3.75 µg of an adjuvanted A H1N1 vaccine in two applications 21 days apart.

Biological: Adjuvanted vaccine against H1N1 influenza virus (GSK)

7.5 µg of the vaccine on days 0 and 21

EXPERIMENTAL

Patients infected with HIV will receive 7.5µg of an adjuvanted A H1N1 vaccine in two applications 21 days apart.

Biological: Adjuvanted vaccine against H1N1 influenza virus (GSK)

3.75 µg of the vaccine on day 0

ACTIVE COMPARATOR

The volunteers in the control group will receive a single application of 3.75 µg dose of the vaccine.

Biological: Adjuvanted vaccine against H1N1 influenza virus (GSK)

Interventions

Adjuvanted vaccine against H1N1 influenza virus (GSK) BIOLOGICAL

Patients infected with HIV will receive 3.75 µg of an adjuvanted A H1N1 vaccine in two applications 21 days apart.

3.75 µg of the vaccine on days 0 and 21

Eligibility Criteria

• Age: 18 Years - 59 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Both genders, aged between 18 and 59 years;
• Capacity to give informed consent voluntarily to participate in the study;
• Study participants with reproductive potential (defined as girls after menarche or women who have not reached menopause at least during 24 consecutive months, or who menstruated during the past 24 months, or have not undergone surgical sterilization) must have pregnancy test negative results, in blood or urine, at screening and in the vaccine application days. If they have sexual practices likely to promote pregnancy, the participants must use some form of contraception during the study period. At least one of the following methods MUST be properly used: Condoms (male or female, Hormonal contraceptive.
• Laboratory results in the study screening: hemoglobin \> 8.0 g/dL; Direct bilirubin \< 2.5 x the upper limit of normal; Alanine aminotransferase, ALT (SGPT) and aspartate aminotransferase, AST (SGOT) \< 3 x the upper limit of normal; Platelet count \> 100.000/mm3
• HIV-1 infection (as evidenced by rapid HIV testing or ELISA kit approved and confirmed by repeating the ELISA, IFA, Western blot, HIV-1 plasma viral load) at any time before entering the study.
• Without changing the antiretroviral treatment within 8 weeks prior to the screening for the study: If the volunteer is receiving HAART he/she is required to be using the same regimen within at least 8 weeks before screening. Changes in antiretroviral dosage within 8 weeks prior to entering the study are permitted. In addition, the exchange of pharmacological formulation (eg. the conventional formulation for combination formulations) is allowed. If the volunteer is not on regular antiretroviral treatment, he/she should not have received any dose of any antiretroviral within 8 weeks prior to screening, including for the prevention of HIV vertical transmission (previous prophylactic and therapeutic regimens are allowed)
• Without planning to change or start HAART in the next 6 months.
• HIV-negative test result documented by rapid test approved in Brazil
• Health professionals with indication of receiving H1N1 virus vaccine

You may not qualify if:

• Use of any systemic anticancer or immunomodulator treatment, corticosteroid, experimental vaccines, interleukins, interferons, growth factors or intravenous immunoglobulin (IVIG) within 45 days prior to entry into the study.
• Pregnancy or lactation.
• Allergy and/or sensitivity or any known hypersensitivity to residues present in the vaccine (egg, chicken protein, egg albumin, formaldehyde, gentamicin sulphate and sodium deoxycholate) and/or thimerosal.
• Use of alcohol or addiction or other conditions which in the opinion of the site's investigator, may interfere with compliance to the study requirements.
• D5. Serious illness requiring systemic treatment and/or hospitalization within 45 days prior to entry into the study
• Severe febrile illness or acute infection at the time of screening for the study and/or days of vaccination
• Vaccination against seasonal influenza in the last 12 months prior to study entry
• Previous vaccination against influenza A H1N1
• History or family history of Guillain-Barré Syndrome (parents, siblings, half-siblings or children).
• Diagnosis of neurological condition including (but not limited to) the absence of deep tendon reflexes, Achilles and patellar, in both legs (four missing) in the last six months.
• Disproportionate force loss in lower limb(s) compared to the upper limbs in the last six months.

Sponsors & Collaborators

• Oswaldo Cruz Foundation: lead
• Ministry of Health, Brazil: collaborator

Study Sites (1)

Instituto de Pesquisa Clinica Evandro Chagas (IPEC) - Fiocruz

Rio de Janeiro, Brazil

Location

Related Publications (1)

• Santini-Oliveira M, Camacho LA, Souza TM, Luz PM, Vasconcellos MT, Giacoia-Gripp CB, Morgado MG, Nunes EP, Lemos AS, Ferreira AC, Moreira RI, Veloso VG, Siqueira MM, Grinsztejn B. H1N1pdm09 adjuvanted vaccination in HIV-infected adults: a randomized trial of two single versus two double doses. PLoS One. 2012;7(6):e39310. doi: 10.1371/journal.pone.0039310. Epub 2012 Jun 25.

  PMID: 22761759 DERIVED

MeSH Terms

Conditions

HIV Infections; Orthomyxoviridae Infections

Interventions

halofantrine

Condition Hierarchy (Ancestors)

Blood-Borne Infections; Communicable Diseases; Infections; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Medical doctor

Study Record Dates

• First Submitted: June 29, 2010
• First Posted: July 1, 2010
• Study Start: March 1, 2010
• Primary Completion: March 1, 2012
• Study Completion: April 1, 2012
• Last Updated: July 18, 2018

Record last verified: 2018-07

Locations

BR (1)